Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $53
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. CLDX | 0.00 |
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:
CLDX) with a Overweight and raises the price target from $48 to $53.